Trials / Completed
CompletedNCT03088527
Phase 1, First-in-Human Study of RAD140 in Postmenopausal Women With Breast Cancer
A Phase 1, First-in-Human, Multi-Part Study of RAD140 in Postmenopausal Women With Hormone Receptor Positive Breast Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- Stemline Therapeutics, Inc. · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this study is to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
Detailed description
This is a first in humans study that is designed to evaluate the clinical safety profile, tolerability, and pharmacokinetic (PK) characteristics of RAD140 in hormone receptor positive breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | RAD140 | RAD140 will be supplied as formulated drug-in-capsules for oral administration. |
Timeline
- Start date
- 2017-10-23
- Primary completion
- 2020-08-28
- Completion
- 2020-09-24
- First posted
- 2017-03-23
- Last updated
- 2022-08-18
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03088527. Inclusion in this directory is not an endorsement.